Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;27(9):1384-1390.
doi: 10.1177/1352458520964409. Epub 2020 Oct 15.

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

Robert A Bermel  1 , Janel K Fedler  2 , Peter Kaiser  3 , Cindy Novalis  4 , Jeff Schneebaum  4 , Elizabeth A Klingner  2 , Dawn Williams  4 , Jon W Yankey  2 , Dixie J Ecklund  2 , Marianne Chase  5 , Robert T Naismith  6 , Eric C Klawiter  7 , Andrew D Goodman  8 , Christopher S Coffey  2 , Robert J Fox  1
Affiliations
Randomized Controlled Trial

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

Robert A Bermel et al. Mult Scler. 2021 Aug.

Abstract

Background: The SPRINT-MS trial demonstrated benefit of ibudilast on brain atrophy over 96 weeks in progressive multiple sclerosis (MS). Optical coherence tomography (OCT) was performed in all trial participants.

Objective: Report the OCT results of the SPRINT-MS trial.

Methods: OCT was obtained at baseline and every 6 months using spectral domain OCT and analyzed by an OCT reading center. Change in each OCT outcome measure by treatment group was estimated using linear mixed models.

Results: Change in pRNFL thickness was +0.0424 uM/year (95% confidence interval (CI): -0.3091 to 0.3939) for ibudilast versus -0.2630 uM (95% CI: -0.5973 to 0.0714) for placebo (n = 244, p = 0.22). Macular volume change was -0.00503 mm3/year (-0.02693 to 0.01688) with ibudilast versus -0.03659 mm3/year (-0.05824 to -0.01494) for placebo in the Spectralis cohort (n = 61, p = 0.044). For the Cirrus cohort, macular volume change was -0.00040 mm3/year (-0.02167, 0.020866) with ibudilast compared to -0.02083 mm3/year (-0.04134 to -0.00033) for placebo (n = 183, p = 0.1734). Ganglion cell-inner plexiform layer thickness change, available from Cirrus, was -0.4893 uM/year (-0.9132, -0.0654) with ibudilast versus -0.9587 uM/year (-1.3677, -0.5498) with placebo (n = 183, p = 0.12).

Conclusion: Retinal thinning in MS may be attenuated by ibudilast. Sample size estimates suggest OCT can be a viable outcome measure in progressive MS trials if a therapy has a large treatment effect.

Trial registration: NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942.

Keywords: Optical coherence tomography; ibudilast; multiple sclerosis; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

Disclosures:

RB: has served as a consultant for Biogen, Genzyme, Genentech, and Novartis. He receives research support from Biogen, Genentech, and Novartis, and shares rights to intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen.

JF: The Author declares that there is no conflict of interest

PK: has received personal compensation from Carl Zeiss Medtec

CN: The Author declares that there is no conflict of interest

JS: The Author declares that there is no conflict of interest

EK: The Author declares that there is no conflict of interest

DW: The Author declares that there is no conflict of interest

JY: The Author declares that there is no conflict of interest

DE: The Author declares that there is no conflict of interest

MC: The Author declares that there is no conflict of interest

RTN: has consulted for Alexion, Alkermes, Bayer AG, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, TG Therapeutics, Viela Bio.

ECK has received consulting fees from Alexion, Atlas5D, Biogen, Celgene, EMD Serono, Genentech and MedDay and research funding from AbbVie, Atlas5D, Biogen, EMD Serono, Genzyme, and Roche.

ADG: has received personal compensation for consulting from Adamas, EMD-Serono, MedDay, Greenwich Bioscience, Celgene, Teva, Sun Pharma, Novartis, Sanofi Genzyme, Genentech-Roche, Biogen, Atara, Acorda Therapeutics and received research support from Teva, Sun Pharma, Novartis, Sanofi Genzyme, Genentech-Roche, Biogen, Atara, Acorda Therapeutics.

KN has received personal licensing fee from Biogen, consulting fee from NeuroRx, and speaking fee from Sanofi Genzyme and research grant funding from Biogen, Novartis, and Sanofi Genzyme.

CSC The Author declares that there is no conflict of interest

RJF has received personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi Gensyme, Teva, and TG therapeutics; served on advisory committees for Actelion, Biogen, Immunic, and Novartis; and received clinical trial contract and research grant funding from Novartis.

Figures

Figure 1:
Figure 1:
Model-based change in OCT measures over time by treatment group
See this image and copyright information in PMC

References

    1. Gibson LC, Hastings SF, McPhee I, et al.The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006; 538: 39–42. 2006/05/06. DOI: S0014–2999(06)00201–9 [pii] 10.1016/j.ejphar.2006.02.053. - DOI - PubMed
    1. Cho Y, Crichlow GV, Vermeire JJ, et al.Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A 2010; 107: 11313–11318. 2010/06/11. DOI:10.1073/pnas.1002716107. - DOI - PMC - PubMed
    1. Ruiz-Perez D, Benito J, Polo G, et al.The Effects of the Toll-Like Receptor 4 Antagonist, Ibudilast, on Sevoflurane’s Minimum Alveolar Concentration and the Delayed Remifentanil-Induced Increase in the Minimum Alveolar Concentration in Rats. Anesth Analg 2016; 122: 1370–1376. 2016/02/10. DOI: 10.1213/ANE.0000000000001171. - DOI - PubMed
    1. Sanftner LM, Gibbons JA, Gross MI, et al.Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica 2009; 39: 964–977. 2009/11/21. DOI: 10.3109/00498250903254340. - DOI - PubMed
    1. Ontaneda D, Fox RJ and Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–223. 2015/03/17. DOI: 10.1016/S1474-4422(14)70264-9S1474-4422(14)70264-9 [pii]. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources